The non–sentinel node (NSN) prediction nomogram for estrogen receptor (ER)-positive, HER2-negative breast cancer patients, developed at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City, may deliver significant medical and economic benefits, a new study confirms.
Investigators from Institut Curie in Paris evaluated the medico-economic effect of using the MSKCC NSN prediction nomogram in 1,036 patients who were treated for operable ER-positive, HER2-negative breast cancer